Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis
ABSTRACT Objective To assess safety of the switch between natalizumab and fingolimod without a washout period. Methods Prospective data on 25 JCV positive patients who underwent this medication switch were collected and analyzed. Results After a median period of nine months from the medication...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Revinter Publicações
2016-08-01
|
| Series: | Arquivos de Neuro-Psiquiatria |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2016000800650&lng=en&tlng=en |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850210578565431296 |
|---|---|
| author | Yara Dadalti Fragoso Soniza Vieira Alves-Leon Jefferson Becker Joseph Bruno Bidin Brooks Eber Castro Correa Alfredo Damasceno Paulo Diniz da Gama Rodrigo Assad da Gama Andre Palma da Cunha Matta Ernane Pires Maciel Thereza Cristina d’Avila Winckler |
| author_facet | Yara Dadalti Fragoso Soniza Vieira Alves-Leon Jefferson Becker Joseph Bruno Bidin Brooks Eber Castro Correa Alfredo Damasceno Paulo Diniz da Gama Rodrigo Assad da Gama Andre Palma da Cunha Matta Ernane Pires Maciel Thereza Cristina d’Avila Winckler |
| author_sort | Yara Dadalti Fragoso |
| collection | DOAJ |
| description | ABSTRACT Objective To assess safety of the switch between natalizumab and fingolimod without a washout period. Methods Prospective data on 25 JCV positive patients who underwent this medication switch were collected and analyzed. Results After a median period of nine months from the medication switch, there were no safety issues to report. The patients had good disease control and no adverse events were reported. Conclusion Washout may not be necessary in daily practice when switching from natalizumab to fingolimod. Expertise on multiple sclerosis management, however, is essential for drug switching. |
| format | Article |
| id | doaj-art-92741c2f77a94180a52a296e59ac04c0 |
| institution | OA Journals |
| issn | 1678-4227 |
| language | English |
| publishDate | 2016-08-01 |
| publisher | Thieme Revinter Publicações |
| record_format | Article |
| series | Arquivos de Neuro-Psiquiatria |
| spelling | doaj-art-92741c2f77a94180a52a296e59ac04c02025-08-20T02:09:45ZengThieme Revinter PublicaçõesArquivos de Neuro-Psiquiatria1678-42272016-08-0174865065210.1590/0004-282X20160090S0004-282X2016000800650Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosisYara Dadalti FragosoSoniza Vieira Alves-LeonJefferson BeckerJoseph Bruno Bidin BrooksEber Castro CorreaAlfredo DamascenoPaulo Diniz da GamaRodrigo Assad da GamaAndre Palma da Cunha MattaErnane Pires MacielThereza Cristina d’Avila WincklerABSTRACT Objective To assess safety of the switch between natalizumab and fingolimod without a washout period. Methods Prospective data on 25 JCV positive patients who underwent this medication switch were collected and analyzed. Results After a median period of nine months from the medication switch, there were no safety issues to report. The patients had good disease control and no adverse events were reported. Conclusion Washout may not be necessary in daily practice when switching from natalizumab to fingolimod. Expertise on multiple sclerosis management, however, is essential for drug switching.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2016000800650&lng=en&tlng=enesclerose múltiplanatalizumabcloridrato de fingolimodeterapêutica |
| spellingShingle | Yara Dadalti Fragoso Soniza Vieira Alves-Leon Jefferson Becker Joseph Bruno Bidin Brooks Eber Castro Correa Alfredo Damasceno Paulo Diniz da Gama Rodrigo Assad da Gama Andre Palma da Cunha Matta Ernane Pires Maciel Thereza Cristina d’Avila Winckler Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis Arquivos de Neuro-Psiquiatria esclerose múltipla natalizumab cloridrato de fingolimode terapêutica |
| title | Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis |
| title_full | Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis |
| title_fullStr | Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis |
| title_full_unstemmed | Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis |
| title_short | Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis |
| title_sort | safety of switching from natalizumab straight into fingolimod in a group of jcv positive patients with multiple sclerosis |
| topic | esclerose múltipla natalizumab cloridrato de fingolimode terapêutica |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2016000800650&lng=en&tlng=en |
| work_keys_str_mv | AT yaradadaltifragoso safetyofswitchingfromnatalizumabstraightintofingolimodinagroupofjcvpositivepatientswithmultiplesclerosis AT sonizavieiraalvesleon safetyofswitchingfromnatalizumabstraightintofingolimodinagroupofjcvpositivepatientswithmultiplesclerosis AT jeffersonbecker safetyofswitchingfromnatalizumabstraightintofingolimodinagroupofjcvpositivepatientswithmultiplesclerosis AT josephbrunobidinbrooks safetyofswitchingfromnatalizumabstraightintofingolimodinagroupofjcvpositivepatientswithmultiplesclerosis AT ebercastrocorrea safetyofswitchingfromnatalizumabstraightintofingolimodinagroupofjcvpositivepatientswithmultiplesclerosis AT alfredodamasceno safetyofswitchingfromnatalizumabstraightintofingolimodinagroupofjcvpositivepatientswithmultiplesclerosis AT paulodinizdagama safetyofswitchingfromnatalizumabstraightintofingolimodinagroupofjcvpositivepatientswithmultiplesclerosis AT rodrigoassaddagama safetyofswitchingfromnatalizumabstraightintofingolimodinagroupofjcvpositivepatientswithmultiplesclerosis AT andrepalmadacunhamatta safetyofswitchingfromnatalizumabstraightintofingolimodinagroupofjcvpositivepatientswithmultiplesclerosis AT ernanepiresmaciel safetyofswitchingfromnatalizumabstraightintofingolimodinagroupofjcvpositivepatientswithmultiplesclerosis AT therezacristinadavilawinckler safetyofswitchingfromnatalizumabstraightintofingolimodinagroupofjcvpositivepatientswithmultiplesclerosis |